Andrea L. Pusic

Andrea L. Pusic

Auto-generated profile, based on publicly available information

Andrea L. Pusic

Patient Reported Outcomes, Value, and Experience (PROVE) Center, Brigham and Women's Hospital, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in JAMA Surgery
Verified
Journal Article
Closed access
PDF file
KSKatherine B. Santosa
Katherine B. Santosa
JQJi Qi
Ji Qi
HKHyungjin M. Kim
Hyungjin M. Kim
JHJennifer B. Hamill
Jennifer B. Hamill
EWEdwin G. Wilkins
Edwin G. Wilkins
APAndrea L. Pusic
Andrea L. Pusic
Importance Previous outcome studies comparing implant and autologous breast reconstruction techniques have been limited by short-term follow-up, single-center design, and a lack of rigorous patient-reported outcome data. An understanding of the expected satisfaction and breast-related quality of life associated with each type of procedure is central to the decision-making process. Objective To determine outcomes reported by patients undergoing postmastectomy breast reconstruction using implant or autologous techniques 2 years after surgery. Design, Setting, and Participants Patients were recruited from 11 centers (57 plastic surgeons) across North America for the Mastectomy Reconstruction Outcomes Consortium study, a prospective, multicenter trial, from February 1, 2012, to July 31, 2015. Women undergoing immediate breast reconstruction using implant or autologous tissue reconstruction after mastectomy for cancer treatment or prophylaxis were eligible. Overall, 2013 women (1490 implant and 523 autologous tissue reconstruction) met the inclusion criteria. All patients included in this analysis had 2 years of follow-up. Exposures Procedure type (ie, implant vs autologous tissue reconstruction). Main Outcomes and Measures The primary outcomes of interest were scores on the BREAST-Q, a validated, condition-specific, patient-reported outcome instrument, which were collected prior to and at 2 years after surgery. The following 4 domains of the BREAST-Q reconstruction module were evaluated: satisfaction with breasts, psychosocial well-being, physical well-being, and sexual well-being. Responses from each scale were summed and transformed on a 0 to 100 scale, with higher numbers representing greater satisfaction or quality of life. Results Of the 2013 women in the study (mean [SD] age, 48.1 [10.5] years for the group that underwent implant-based reconstruction and 51.6 [8.7] years for the group that underwent autologous reconstruction), 1217 (60.5%) completed questionnaires at 2 years after reconstruction. After controlling for baseline patient characteristics, patients who underwent autologous reconstruction had greater satisfaction with their breasts (difference, 7.94; 95% CI, 5.68-10.20;P < .001), psychosocial well-being (difference, 3.27; 95% CI, 1.25-5.29;P = .002), and sexual well-being (difference, 5.53; 95% CI, 2.95-8.11;P < .001) at 2 years compared with patients who underwent implant reconstruction. Conclusions and Relevance At 2 years, patients who underwent autologous reconstruction were more satisfied with their breasts and had greater psychosocial well-being and sexual well-being than did those who underwent implant reconstruction. These findings can inform patients and their clinicians about expected satisfaction and quality of life outcomes of autologous vs implant-based procedures and further support the adoption of shared decision making in clinical practice.

1 December 2019 in Plastic and Reconstructive Surgery
Verified
Journal Article
Closed access
JNJonas A. Nelson
Jonas A. Nelson
SVSophocles H. Voineskos
Sophocles H. Voineskos
JQJi Qi
Ji Qi
HKHyungjin M. Kim
Hyungjin M. Kim
JHJennifer B. Hamill
Jennifer B. Hamill
APAndrea L. Pusic
Andrea L. Pusic
Background: Rates of breast reconstruction following mastectomy continue to increase. The objective of this study was to determine the frequency of elective revision surgery and the number of procedures required to achieve a stable breast reconstruction 2 years after mastectomy. Methods: Women undergoing first-time breast reconstruction after mastectomy were enrolled and followed for 2 years, with completion of reconstruction occurring in 1996. Patients were classified based on the absence or presence of complications. Comparisons within cohorts were performed to determine factors associated with revisions and total procedures. Mixed-effects regression modeling identified factors associated with elective revisions and total operations. Results: Overall, 1534 patients (76.9 percent) had no complications, among whom 40.2 percent underwent elective revisions. The average number of elective revisions differed by modality (p < 0.001), with abdominally based free autologous reconstruction patients undergoing the greatest number of elective revisions (mean, 0.7). The mean total number of procedures also differed (p < 0.001), with tissue expander/implant reconstruction patients undergoing the greatest total number of procedures (mean, 2.4). Complications occurred in 462 patients (23.1 percent), with 67.1 percent of these patients undergoing elective revisions, which was significantly higher than among patients without complications (p < 0.001). The mean number of procedures again differed by modality (p < 0.001) and followed similar trends, but with an increased mean number of revisions and procedures overall. Mixed-effects regression modeling demonstrated that patients experiencing complications had increased odds of undergoing elective revision procedures (OR, 3.2; p < 0.001). Conclusions: Breast reconstruction patients without complications undergo over two procedures on average to achieve satisfactory reconstruction, with 40 percent electing revisions. If a complication occurs, the number of procedures increases. CLINICAL QUESTION/LEVEL OF EVIDENCE: Risk, II.

29 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MCMichelle Coriddi
Michelle Coriddi
JDJoseph Dayan
Joseph Dayan
NSNikhil Sobti
Nikhil Sobti
DNDavid Nash
David Nash
JGJohanna Goldberg
Johanna Goldberg
Babak J. MehraraBabak J. Mehrara
Babak J. Mehrara
Introduction: Analysis of quality of life (QOL) outcomes is an important aspect of lymphedema treatment since this disease can substantially impact QOL in affected individuals. There are a growing number of studies reporting patient-reported outcomes (PROMs) for patients with lymphedema. The purpose of this study was to conduct a systematic review of outcomes and utilization of PROMs following surgical treatment of lymphedema. Methods: A literature search of four databases was performed up to and including March, 2019. Studies included reported on QOL outcomes after physiologic procedures, defined as either lymphovenous bypass (LVB) or vascularized lymph node transplant (VLNT), to treat upper and/or lower extremity primary or secondary lymphedema. Results: In total, 850 studies were screened—of which, 32 studies were included in this review. Lymphovenous bypass was the surgical intervention in 16 studies, VLNT in 11 studies, and both in 5 studies. Of the 32 total studies, 16 used validated survey tools. The most commonly used PROM was the lymph quality of life measure for limb lymphedema (LYMQOL) (12 studies). In the remaining four studies, the upper limb lymphedema 27 scale (ULL27), the short form 36 questionnaire (SF-36), the lymphedema functioning, disability and health questionnaire (Lymph-ICF), and lymphedema life impact scale (LLIS) were each used once. QOL improvement following surgical treatment was noted in all studies. Conclusions: Physiologic surgical treatment of lymphedema results in improved QOL outcomes in most patients. The use of validated PROM tools is increasing but there is no current consensus on use. Future research to evaluate the psychometric properties of PROMs in lymphedema is needed to guide the development and use of lymphedema-specific tools.

21 January 2020 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
AKAnne F. Klassen
Anne F. Klassen
LDLaura Dominici
Laura Dominici
SFSarah Fuzesi
Sarah Fuzesi
SCStefan J. Cano
Stefan J. Cano
DADunya Atisha
Dunya Atisha
APAndrea L. Pusic
Andrea L. Pusic

5 July 2021 in Annals of Surgical Oncology
Verified
Journal Article
Open access
PDF file
AKAnne F. Klassen
Anne F. Klassen
ETElena Tsangaris
Elena Tsangaris
MKManraj Nirmal Kaur
Manraj Nirmal Kaur
LPLotte Poulsen
Lotte Poulsen
LBLouise M. Beelen
Louise M. Beelen
APAndrea L. Pusic
Andrea L. Pusic
Background: A multiphased mixed-methods study was performed to develop and validate a comprehensive patient-reported outcome measure (PROM) for arm lymphedema in women with breast cancer (i.e., the LYMPH-Q Upper Extremity Module). Methods: Qualitative interviews (January 2017 and June 2018) were performed with 15 women to elicit concepts specific to arm lymphedema after breast cancer treatment. Data were audio-recorded, transcribed, and coded. Scales were refined through cognitive interviews (October and Decemeber 2018) with 16 patients and input from 12 clinical experts. The scales were field-tested (October 2019 and January 2020) with an international sample of 3222 women in the United States and Denmark. Rasch measurement theory (RMT) analysis was used to examine reliability and validity. Results: The qualitative phase resulted in six independently functioning scales that measure arm symptoms, function, appearance, psychological function, and satisfaction with information and with arm sleeves. In the RMT analysis, all items in each scale had ordered thresholds and nonsignificant chi-square p values. For all the scales, the reliability statistics with and without extremes for the Person Separation Index were 0.80 or higher, Cronbach’s alpha was 0.89 or higher, and the Intraclass Correlation Coefficients were 0.92 or higher. Lower (worse) scores on the LYMPH-Q Upper Extremity scales were associated with reporting of more severe arm swelling, an arm problem caused by cancer and/or its treatment, and wearing of an arm sleeve in the past 12 months. Conclusions: The LYMPH-Q Upper Extremity Module can be used to measure outcomes that matter to women with upper extremity lymphedema. This new PROM was designed using a modern psychometric approach and, as such, can be used in research and in clinical care.

1 January 2019 in Clinics in Plastic Surgery
Verified
Journal Article
Closed access
LPLotte Poulsen
Lotte Poulsen
GMGiancarlo McEvenue
Giancarlo McEvenue
AKAnne Klassen
Anne Klassen
MHMaarten Hoogbergen
Maarten Hoogbergen
JSJens Ahm Sørensen
Jens Ahm Sørensen
APAndrea Pusic
Andrea Pusic